Pielotax®
Biologically active food supplement PIELOTAX® contains a complex of low molecular weight peptides
with a molecular weight of up to 5000 Da, isolated from kidney tissues of young animals - calves up
to 12 months of age or pigs.
PIELOTAX® is available in capsules with an active substance content of 10 mg.
PIELOTAX® peptides regulate metabolic processes in kidney tissue cells, increase the reserve ca-
pacity of the urinary system, have a beneficial effect on the body’s adaptation processes in extreme
conditions, and have antioxidant properties, regulating the processes of peroxidation in the kidneys.
Experimental studies have shown that peptides have a tissue-specific effect on the cells of those tis-
sues from which they are isolated. This allows us to assume the effectiveness of PIELOTAX® for the
restoration of kidney function in case of disorders of various origins.
Metabolic disorders, hypertension, infectious and autoimmune lesions, especially with age, often lead
to kidney damage (3).
Drug treatment of kidney disease includes the use of the following drugs (1, 2):
- Drugs of the 4-aminoquinoline range - delagil, plaquenil;
- Immunomodulators - thymalin, levamisole;
- Antihypertensive drugs;
- Vitamins C and E (antioxidants);
- etc.
The clinical study of PIELOTAX® was carried out at the Medical Center of the St. Petersburg Institute
of Bioregulation and Gerontology from February to August 2011.
Clinical trials of PIELOTAX® were carried out in patients with gouty nephropathy. A total of 42 patients
took part in the study. The distribution of patients by sex and age is presented in Table 1. Patients
with gouty nephropathy complained of recurrent pain in the joints. In connection with the prolonged
course of the disease in a number of patients, the inflammatory changes carried obliterated traits.
All patients previously received symptomatic and pathogenetic therapy for the disease, which con-
tributed to a temporary decrease in the severity of symptoms.
The patients were randomized into 2 groups - the control group (15 people) and the primary group
(27 people). Patients in the control group received only conventional therapy.
In addition to conventional therapy, patients of the primary group received PIELOTAX® orally 10-
15 minutes before meals, 1-2 capsules 3 times a day for 30 days, depending on the severity of the
pathological process.
Distribution of patients by diagnosis, sex and age. Table 1
Diagnosis Age Group Male Female Total
Gouty nephropathy 43-67 Control 9 6 15
42-68 Primary 19 8 27
Total: 28 14 42
RESEARCH METHODS
The patients’ complaints were assessed in dynamics, a general clinical examination of blood and urine, a
biochemical study of blood on the REFLOTRON apparatus (Boehringer Mannheim, Germany) were carried
out. Ultrasound examination of the kidneys was performed using an ultrasound machine (ALOKA, Japan).
Для таблиц, дозировок и примечаний сверяйтесь с оригинальным PDF: при извлечении текста порядок колонок может измениться.
Из библиотеки Peptides. Авторство и содержание оригинала сохранены. Размещено с разрешения поставщика.